PAVmed, a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, has officially announced the launch of a wholly owned incubator called PMX, which will advance its existing line-up of technologies. According to certain reports, these technologies include PortIO™ Implantable Intraosseous Vascular Access Device (PortIO), EsoCure™ Esophageal Ablation Device (EsoCure), and CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome (CarpX). Talk about how the update will materialize on a slightly deeper level, we begin from PortIO, which will now come decked up with an implantable intraosseous vascular access device and insertion kit. Markedly enough, though, instead of having catheter located in a vein, it will feature a short extension from the device. This extension is what a physician will insert into a bone, thus leaving the device to reside completely beneath the skin. Such an arrangement makes it possible for the uset to have a direct access to the bone marrow, also known as a well-established route for the delivery of medications, fluids, and other substances. Anyway, one can insert and remove the new PortIO near-percutaneously without requiring a surgical pocket or significant dissection, as well as without any need to avail radiologic confirmation of proper deployment. This becomes only more impressive once you consider that, back in 2022; the device also completed IRB-approved First-in-Human studies. Then, it had displayed an excellent device function and no complications whatsoever across a total of nine participating subjects.
Next up, we have the EsoCure Esophageal Ablation Device, which is ablation system designed to treat late esophageal precancer (dysplastic Barrett’s Esophagus). To do so, it brings single-use, disposable balloon catheters that are delivered through the working channel of a standard endoscope and a low-cost console to control the ablation process. There is also a proprietary Caldus™ technology integrated within the EsoCure system, basically referring to a catheter design that ensures controlled direct thermal tissue ablation without the need for an intermediate energy source, such as radiofrequency. Making the system’s case even stronger is the extensive development work that backs its prowess. This development work includes numerous animal studies, where we saw how EsoCure created ablation lesions similar or superior to those of the main commercially available radiofrequency esophageal ablation device.
Rounding up highlights is the CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome. CarpX is essentially a patented single-use disposable minimally invasive device designed to treat carpal tunnel syndrome, and at the same time, cut back on otherwise lengthy recovery times. Already boasting a U.S. Food and Drug Administration (FDA) 510(k) clearance, the device in question should be able to closely mimic the anatomic results of invasive carpal tunnel surgery, but much less invasively. But how will it manage that promise of minimal invasiveness? Well, the answer resides in a mix of catheters, balloons, radiofrequency energy and other established tools, a mix which has previously contributed towards percutaneous and minimally invasive revolutions in the treatment of other conditions.
PAVmed will carry out the entire effort in collaboration with Hatch Medical.
“We have been impressed with the commercial potential of these technologies and the meticulous, high-caliber work that the PAVmed team and its partners have put into their development to date,” said Paul Gianneschi, Managing Principal of Hatch Medical. “We are excited to leverage our product leadership, industry expertise and other resources to help PAVmed bring these novel technologies to market, as we have successfully done for decades with other entrepreneurs and early-stage companies.”
